Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)

Summary: This study assessed the clinical efficacy and safety of neutralizing monoclonal antibodies (mABs) for outpatients with COVID-19. The findings showed that patients who received neutralizing mABs had a significantly lower rate of hospitalization or emergency department (ED) visits compared to those who received a placebo. The mortality rate was also significantly lower in the neutralizing mAB group. Neutralizing mABs were associated with a similar risk of any adverse events (AEs) compared to a placebo, but a lower risk of serious AEs.

Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.

Summary: REGEN-COV reduced the risk of Covid-19-related hospitalization or death, resolved symptoms, and reduced the SARS-CoV-2 viral load more rapidly than the placebo.